Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction
NCT07820410Phase 3Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Composite event of all-cause mortality, heart transplantation or left ventricular assist device implantation due to heart failure, heart failure-related rehospitalization post-procedure and… at 12 months. Started Nov 2024; status: recruiting.
02
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07820410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820410.